Labcorp (LH) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Leadership and organizational updates

• Newly appointed CFO Julia Wang brings extensive diagnostics and biopharma experience, succeeding Glenn Eisenberg after his decade-long tenure.

• Julia Wang highlights her transition, strong team culture, and strategic fit with the company.

2024 performance and 2025 outlook

• Diagnostics and Central Laboratory businesses reported 9% revenue growth in Q3 2024, driven mainly by volume.

• Early Development business declined 11% in Q3 but is expected to return to growth in Q4 and 2025.

• Strong momentum and robust partnership pipeline position the company well for 2025.

• 2025 guidance will be provided with February earnings.

Regulatory and legislative environment

• Closely monitoring LDT regulations and PAMA; concerns include patient access and healthcare disparities.

• PAMA implementation likely in 2026; ongoing efforts to seek a long-term legislative solution.

• SALSA seen as a partial improvement over PAMA, but no perfect solution exists.